Siolta Therapeutics
  1. Companies
  2. Siolta Therapeutics
  3. Products
  4. Siolta - Model STMC-105 - Prevention of ...

SioltaModel STMC-105 - Prevention of Recurrent Bacterial Vaginosis (BV)

SHARE

Bacterial vaginosis is one of the most common women’s health conditions, impacting up to 50% of women globally.  Bacterial vaginosis is associated with disruptions to the protective community of bacteria in the vaginal tract and the colonization by opportunistic microbes.   Standard of care treatments using antibiotics can be effective at treating bacterial vaginosis by reducing microbial burden, however these approaches fail to address the critical need to establish a stable and protective microbiota for long-term vaginal health and prevention of disease recurrence.

Most popular related searches

To address this unmet need, Siolta Therapeutics is applying deep characterization of metabolic crosstalk and functional ecology within vaginal microbial communities to develop the microbial consortium STMC-105. This synergistic multi-strain LBP is designed to provide maximum resilience from vaginal microbiota community disruption, opportunistic pathobiont colonization, and recurrence of symptomatic bacterial vaginosis.